Oxford, UK – 8 August 2025 – Sitryx Therapeutics (“the Company”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory ...

Viracta Therapeutics (VIRX) announced that the company has implemented a reprioritization of resources intended to enhance the company’s focus on its Nana-val development program in patients with ...

Lexicon Pharmaceuticals, Inc. LXRX announced a strategic review, including the reprioritization of its current portfolio of marketed products and pipeline candidates and reducing operational expenses, ...